The complex biology of the receptor for the insulin-like growth factor-1

被引:30
作者
Romano, G [1 ]
机构
[1] Thomas Jefferson Univ, Jefferson Hosp Neurosci, Jefferson Med Coll, Farber Inst Neurosci,Dept Neurosurg, Philadelphia, PA 19107 USA
关键词
D O I
10.1358/dnp.2003.16.8.829351
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The receptor for the insulin-like growth factor-1 (IGF-1R) controls a wide variety of cellular functions. IGF-1R is a tyrosine kinase receptor that is activated by the binding of a ligand to the extracellular domain. There are three ligands; for IGF-1R: IGF-I, IGF-II and insulin at supraphysiological concentrations. The binding of the ligand activates the catalytic activity of the tyrosine kinase domain, which in turn causes the autophosphorylation of IGF-1R. As a consequence of autophosphorylation, the activated IGF-1R sends a potent mitogenic signal to the cell nucleus. It has been clearly shown that an overexpressed and activated IGF-1R is quasi-obligatory for the establishment of a malignant cell phenotype. Interestingly, the targeting of IGF-1R can reverse the malignant phenotype in cancer cells, without affecting the biology of normal cells. For these reasons, IGF-1R seems to be a very promising candidate target for cancer therapy. In addition, IGF-1R protects cells from apoptosis and promotes cell growth and proliferation. However, more recent studies have also shown that IGF-1 R regulates cell adhesion and motility, and, in certain cellular contexts, can induce differentiation. Indeed, the biology of the IGF-1 R appears more complex than previously thought. The goal of this review is to describe the multiple functions displayed by IGF-1 R in cell biology. (C) 2003 Prous Science. All rights reserved.
引用
收藏
页码:525 / 531
页数:7
相关论文
共 54 条
  • [1] EXPRESSION OF INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II AND THEIR RECEPTOR MESSENGER-RNAS IN PRIMARY HUMAN ASTROCYTOMAS AND MENINGIOMAS - INVIVO STUDIES USING INSITU HYBRIDIZATION AND IMMUNOCYTOCHEMISTRY
    ANTONIADES, HN
    GALANOPOULOS, T
    NEVILLEGOLDEN, J
    MAXWELL, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (02) : 215 - 222
  • [2] The contradictions of the insulin-like growth factor 1 receptor
    Baserga, R
    [J]. ONCOGENE, 2000, 19 (49) : 5574 - 5581
  • [3] THE PROTEIN ID - A NEGATIVE REGULATOR OF HELIX-LOOP-HELIX DNA-BINDING PROTEINS
    BENEZRA, R
    DAVIS, RL
    LOCKSHON, D
    TURNER, DL
    WEINTRAUB, H
    [J]. CELL, 1990, 61 (01) : 49 - 59
  • [4] MUTANT IGF-I RECEPTORS AS DOMINANT NEGATIVES FOR GROWTH AND TRANSFORMATION
    BURGAUD, JL
    RESNICOFF, M
    BASERGA, R
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 214 (02) : 475 - 481
  • [5] Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras
    Cristofanelli, B
    Valentinis, B
    Soddu, S
    Rizzo, MG
    Marchetti, A
    Bossi, G
    Morena, AR
    Dews, M
    Baserga, R
    Sacchi, A
    [J]. ONCOGENE, 2000, 19 (29) : 3245 - 3255
  • [6] DAmbrosio C, 1996, CANCER RES, V56, P4013
  • [7] INSULIN-LIKE GROWTH-FACTOR-I RECEPTORS IN HUMAN BRAIN AND PITUITARY-GLAND - AN AUTORADIOGRAPHIC STUDY
    DEKEYSER, J
    WILCZAK, N
    DEBACKER, JP
    HERROELEN, L
    VAUQUELIN, G
    [J]. SYNAPSE, 1994, 17 (03) : 196 - 202
  • [8] BIPHASIC CONCENTRATION DEPENDENCY OF STIMULATION OF MYOBLAST DIFFERENTIATION BY SOMATOMEDINS
    FLORINI, JR
    EWTON, DZ
    FALEN, SL
    VANWYK, JJ
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 250 (05): : C771 - C778
  • [9] Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO
  • [10] 2-J